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Summary
The formation of the vascular system is essential for embryonic development and homeostasis.
However, transcriptional control of this process is not fully understood. Here we report an
evolutionarily conserved role for the transcription factor CASZ1 in blood vessel assembly and
morphogenesis. In the absence of CASZ1, Xenopus embryos fail to develop a branched and
lumenized vascular system, and CASZ1-depleted human endothelial cells display dramatic
alterations in adhesion, morphology, and sprouting. Mechanistically, we show CASZ1 directly
regulates Epidermal Growth Factor-Like Domain 7 (Egfl7). We further demonstrate that defects of
CASZ1 or EGFL7-depleted cells are in part due to diminished RhoA expression and impaired
focal adhesion localization. Moreover, these abnormal endothelial cell behaviors in CASZ1-
depleted cells can be rescued by restoration of Egfl7. Collectively, these studies show CASZ1 is
required to directly regulate a unique EGFL7/RhoA-mediated pathway to promote vertebrate
vascular development.
Introduction
Endothelial cells (ECs) are building blocks for the formation of a functional vascular system
during embryonic development. Early stages of blood vessel development occur via
vasculogenesis whereby mesodermal cells differentiate into EC progenitors that
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subsequently proliferate, migrate, and assemble into vascular cords. Cords then undergo
tubulogenesis, or lumen formation, continuing to mature by angiogenesis where vessels
sprout, branch, and remodel. Vessels then become surrounded and stabilized by pericytes
and smooth muscle cells that provide structural support (De Val, 2011; Patan, 2000). The
critical nature of these events is emphasized by observations that disruption of these
processes is associated with human disease states including cancer, stroke, and
atherosclerosis, therefore necessitating a better understanding of transcriptional networks
that regulate these key developmental steps (Carmeliet, 2003; Carmeliet and Jain, 2011;
Potente et al., 2011).
While numerous transcription factors have been discovered to regulate endothelial gene
expression, relatively few factors are necessary for development. Deletions or mutations of a
number of single genes, especially members of Ets and forkhead families, result in moderate
to no vascular phenotypes likely due to functional redundancy (Barton et al., 1998; De Val,
2011; De Val and Black, 2009; Lelievre et al., 2001). Previous studies have implicated the
zinc finger transcription factor CASZ1 in cardiovascular development with depletion of
CASZ1 in Xenopus embryos resulting in failure of a subset of progenitor cells to
differentiate into cardiomyocytes (Christine and Conlon, 2008). Recent genome-wide
association studies have shown a genetic link between human Casz1 and high blood pressure
and hypertension, suggesting a possible role for CASZ1 in EC biology (Levy et al., 2009;
Takeuchi et al., 2010). However, no studies have addressed expression, function, or
transcriptional targets of CASZ1 in vascular tissue.
Despite an essential role for the vasculature in development and disease, our knowledge of
molecular mechanisms controlling these events remains incomplete (De Val and Black,
2009). One protein recently shown to play a role in EC morphogenesis is Epidermal Growth
Factor-Like Domain 7 (Egfl7), an extracellular matrix (ECM) protein expressed exclusively
in EC progenitors and vessels during embryonic and neonatal development. EGFL7 is also
expressed in highly vascularized adult organs and is upregulated upon injury (Campagnolo
et al., 2005; Fitch et al., 2004; Parker et al., 2004). Depletion studies in zebrafish have
defined a role for EGFL7 in tubulogenesis likely through modulation of cell-matrix
interactions (Nikolic et al., 2010; Parker et al., 2004). In addition, overexpression of Egfl7 in
mouse results in abnormal patterning of embryonic and postnatal vasculature (Nichol et al.,
2010). However, the specific function of EGFL7 has been complicated by recent discovery
of microRNA miR-126, the only EC-specific microRNA, within intron 7 of the Egfl7 locus.
While Egfl7 and miR-126 are co-expressed, the function of miR-126 has indicated a distinct
role from its host gene in maintaining vessel integrity and modulating angiogenesis through
repression of targets Spred1 and PIK3R2 (Fish et al., 2008; Kuhnert et al., 2008; Wang et
al., 2008).
In this study, we demonstrate CASZ1 is required for angiogenic sprouting and lumen
morphogenesis. CASZ1 regulates EC contractility, adhesion, and sprouting promoting
assembly and tubulogenesis of blood vessels. Furthermore, we demonstrate CASZ1
activates Egfl7/miR-126 in mammals and Xenopus by directly binding to an intronic
element but does not regulate miR-126 in Xenopus. Moreover, defects associated with
CASZ1-depletion can be phenocopied by EGFL7-depletion, and importantly, rescued by
restoration of Egfl7 levels. We further show CASZ1 transcriptional control of EGFL7
modulates EC behavior through RhoA. Collectively, our studies point to a network whereby
CASZ1 regulates an EGFL7/RhoA-mediated pathway to promote vessel assembly and
morphogenesis.
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EC Expression of CASZ1 is Evolutionarily Conserved
Analysis of Casz1 expression in Xenopus embryos showed transcripts in the vitelline vein
network (vvn) at a stage when the network is primarily made up of vascular ECs and devoid
of smooth muscle cells (Figure 1A)(Christine and Conlon, 2008; Cox et al., 2006; Warkman
et al., 2005) suggesting Casz1 is expressed in vascular ECs. Furthermore, RT-PCR on
vascular explants from late tailbud stage embryos (stage 32) demonstrated that Casz1 is co-
expressed in the vitelline vein region with vascular markers, Msr and Erg (Figure S1A).
Consistently, we found CASZ1 co-localizes with the EC-specific marker PECAM in blood
vessels of mouse embryos (Figure 1B). We have also cloned human Casz1 and showed, as
in Xenopus and mouse, Casz1 is expressed in primary human umbilical vein ECs (HUVEC)
(Figures 1C and 1D). These results taken together with sequence homology and synteny of
CASZ1 across vertebrates (Christine and Conlon, 2008) demonstrate CASZ1 is an
evolutionarily conserved transcription factor expressed in ECs.
CASZ1 is Required for Vascular Patterning and Lumen Morphogenesis
To ascertain the function of CASZ1 in vascular development, we depleted CASZ1 in
Xenopus embryos using a morpholino-based approach (Christine and Conlon, 2008).
Whole-mount in situ hybridization using a panel of EC markers such as Msr and Erg
(Baltzinger et al., 1999; Devic, 1996) demonstrated that at stages when ECs begin to migrate
dorsally from ventral blood islands within the trunk region, there were no noticeable
differences between control and CASZ1-depleted embryos (stage 29, Figures S1B, S1C,
S1J, S1K). However, when ECs begin to assemble into cords (stage 32), defects became
apparent whereby CASZ1-depleted embryos displayed a dramatically reduced vascular
plexus (Figures 2A-2D, S1D--S1E). Extension of intersomitic vessels from posterior
cardinal veins, which is known to occur in Xenopus via sprouting angiogenesis in an
anterior-to-posterior direction (Cleaver et al., 1997; Levine et al., 2003), was also absent or
significantly delayed in CASZ1-depleted embryos (Figures 2A, 2C, 2E, 2G). By mid- to late
tadpole stages (stages 36 and 39), vascular networks of CASZ1-depleted embryos were
comprised of cords which ran predominately in a dorsal-to-ventral pattern and underwent
little to no branching or remodeling (Figures 2E-2H, S1F-S1I, S1L-S1M). Overall, at stage
36, total length of the vitelline vein vasculature and number of branch points and
intersomitic vessels were all significantly decreased in CASZ1-depleted embryos implying a
role for CASZ1 in sprouting and remodeling of the vasculature (Figure 2I). While our
studies focused on vein-derived sprouts, CASZ1-depletion unlikely disrupts arterial/venous
differentiation due to proper specification and localization of the aortic arches (arterial) and
posterior cardinal veins as well as due to the lack of arterial marker expression in veins (data
not shown).
Noting the posterior cardinal veins of CASZ1-depleted embryos appeared thickened (stage
36), we sought to determine the time course of lumen formation in Xenopus. At stage 29,
control and CASZ1-depleted ECs, as marked by Msr, were localized to positions of the
future veins but had not yet undergone lumen formation (Figures 2J, 2N). By stage 32, ECs
separated in control embryos but remained as aggregates in CASZ1-depleted embryos
(Figures 2K, 2O). By stages 36 and 39, the veins of control embryos exhibited well-formed
lumens surrounded by Msr-positive ECs while CASZ1-depleted veins remained closed and
failed to open even at late stages (Figures 2L, 2M, 2P, 2Q). Collectively, these studies
demonstrate CASZ1 is required for angiogenic remodeling and lumen morphogenesis during
vertebrate vascular development.
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Since we have previously established CASZ1 is required for heart development (Christine
and Conlon, 2008), we determined if the vascular requirements for CASZ1 were secondary
to its role in cardiac tissue. Taking advantage of the amenability of Xenopus embryos to
organotypic culture (Mandel et al., 2010), we removed anterior regions of embryos,
including all cardiac tissue at a stage prior to heart formation. Culture of explants showed in
the absence of cardiac tissue, control explants formed vascular networks, as marked by the
EC-specific gene Ami (Inui and Asashima, 2006), that were indistinguishable from un-
manipulated embryos, demonstrating blood flow is not essential for correct patterning of the
early vasculature (Figures S1N, S1P). Critically, we observed severe defects in vascular
networks of CASZ1-depleted explants, strongly suggesting the role of CASZ1 in vascular
development is independent of its role in cardiogenesis (Figures S1O, S1Q).
CASZ1 Regulates EC Behavior
To examine vascular development in more detail and determine if the function of CASZ1 is
evolutionarily conserved, we depleted CASZ1 in HUVECs by lentiviral-mediated short
hairpin RNA (shRNA, 16-fold decrease in Casz1 mRNA; Figure 3A). CASZ1-depleted cells
displayed a thin and elongated morphology in stark contrast to characteristic cobblestone
appearance of uninfected HUVECs or HUVECs infected with control shRNA (Figure 3B).
To determine the precise requirement for CASZ1 and to characterize the dynamics of
CASZ1-depleted HUVECs in real time, we coupled time-lapse imaging with quantitative
analysis. Time-lapse movies showed that CASZ1-depleted cells initially adhered to plastic
or fibronectin-coated substrates but a proportion of cells rounded up and detached (33%,
Figure 3C, Movie S1, data not shown). Of CASZ1-depleted HUVECs that adhered, live
imaging demonstrated the elongated morphology resulted from defects in contractility
whereby the leading edge of CASZ1-depleted cells moved forward without retraction of the
trailing edge (Figure 3C, Movie S1). CASZ1-depleted cells also stopped dividing (0%
shCasz1 vs. 20% control) and consistently, we failed to detect any phospho-histone H3
(pH3)-positive CASZ1-depleted cells (vs. 3% control cells; Figure S2A). Using
fluorescence-activated cell sorting (FACS), we determined CASZ1-depleted ECs were
blocked at the G1/S transition as seen by the significantly reduced number of cells in S-
phase (Figure S2B). Blockage in G1/S progression was not associated with programmed cell
death as determined by cleaved caspase-3 staining (Figure S2C). Furthermore, inability of
CASZ1-depleted cells to maintain adhesion to the substrate was not a secondary
consequence of cell cycle arrest as wildtype HUVECs chemically treated with mitomycin C
did not divide yet remained attached (data not shown). Taken together, these results indicate
CASZ1 has a conserved role in vascular development and is required for EC adhesion,
contractility, and G1/S cell cycle progression.
To assess how adhesive and morphological defects of CASZ1-depleted cells manifested
themselves in vessel assembly, we assessed sprouting using a sprouting angiogenesis assay
in which HUVEC-coated beads were placed in fibrin. While control cells displayed
elongated sprouts with multiple branch points, similar to our findings in Xenopus, CASZ1-
depleted HUVECs had strikingly few sprouts and branches (Figure 3D). Live time-lapse
imaging further showed that CASZ1-depleted cells extended out from beads to initiate
sprout formation but then abruptly detached, indicating that CASZ1 is required for proper
EC adhesion to promote angiogenic sprouting (Movie S4).
Isolation of Egfl7/miR-126 Locus by CASZ1 Chromatin Immunoprecipitation
To identify direct cardiac and endothelial transcriptional targets of CASZ1, we generated a
CASZ1-specific antibody and performed cloning chromatin immunoprecipitation (ChIP)
from dissected cardiovascular Xenopus tissue (stages 27-29, i.e. same time and tissue
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requiring CASZ1)(Figure 4A). We identified 110 putative transcriptional targets including
Egfl7, an ECM protein specifically secreted by ECs shown to be associated with similar
cellular processes as we observe for CASZ1; EC adhesion and vessel tubulogenesis (Figure
4B, Table S1)(Nichol et al., 2010; Nikolic et al., 2010; Parker et al., 2004).
Recently, studies in mouse and zebrafish identified the evolutionarily conserved miR-126
contained within intron 7 of Egfl7 (Fish et al., 2008; Kuhnert et al., 2008; Wang et al.,
2008). We cloned Egfl7 and miR-126 from Xenopus and showed EGFL7 is 47% identical to
human and 45% identical to mouse EGFL7, while Xenopus miR-126 is completely (100%)
conserved between mouse and human (Fitch et al., 2004)(Figure S3A). Genome analysis and
characterization of Xenopus BACs corresponding to the Egfl7/miR-126 locus confirmed
that like other model systems, miR-126 is located within intron 7 of the Xenopus Egfl7
locus (Figure 4B).
Expression analysis revealed Egfl7 is expressed in all major vessels at all stages of
vasculogenesis in Xenopus, as reported for zebrafish, mouse, and human (Figures 4C, 4E,
4G, 4I)(Fitch et al., 2004; Parker et al., 2004). Though Egfl7 and miR-126 have been
reported to be co-transcribed and co-expressed in the vasculature, we found Xenopus
miR-126 has an expression pattern distinct from Egfl7 as well as that reported in other
species (Fish et al., 2008; Wang et al., 2008). Most notably, miR-126 expression is initiated
in ECs at stage 32, slightly later than Egfl7 (stage 29), and we observed strong expression of
miR-126, but not Egfl7, in the developing somites (Figure S3B-S3I). Taken together these
data show that the sequence, genomic arrangement, and vascular expression of Egfl7 and
miR-126 are evolutionarily conserved, however in Xenopus, miR-126 has developed
additional levels of regulation distinct from Egfl7.
Consistent with Egfl7 being a direct target of CASZ1, analysis in CASZ1-depleted embryos
showed Egfl7 was initiated but not maintained in vascular tissues at all stages analyzed
(Figures 4D, 4F, 4H, 4J). Consistently, Egfl7 levels were significantly reduced in CASZ1-
depleted HUVEC (3-fold; Figure 4K). We further observed a dramatic reduction in miR-126
(9-fold) in CASZ1-depleted HUVECs (Figure 4K). These effects were specific as the EC
marker Flk1 was unaltered (Figure 4K). However, we did not observe reduction in miR-126
in CASZ1-depleted Xenopus embryos at mid- and late-tadpole stages (stages 32-39, Figures
S3E, S3G, S3I). Collectively, these studies demonstrate regulation of Egfl7 and miR-126
expression in human ECs is dependent on CASZ1 while Xenopus miR-126 appears to have
evolved a CASZ1-independent mechanism of regulation.
Egfl7 is a Direct Transcriptional Target of CASZ1
To determine whether CASZ1 directly regulates Egfl7, we performed in vivo transcriptional
assays where single copies of intronic regions of Egfl7 corresponding to the putative
CASZ1-bound region (introns 2-5) were placed upstream of a basal promoter driving
luciferase activity. Of these intronic regions, only the 5′ half of intron 3 (E1) resulted in a
dose-dependent, reproducible increase in transcriptional activity in response to CASZ1
(Figures 4L-4M). To determine if CASZ1 endogenously binds to this element in vivo and to
further refine the region within E1, we performed ChIP of endogenous CASZ1 from early
embryos (stage 32), a time point when CASZ1 is required for Egfl7 expression. Results
showed CASZ1 binds to nucleotides 59-173 of intron 3 (E1.2) but not the most 5′ end of E1
(E1.1)(Figure 4N, data not shown). Thus, CASZ1 directly binds to the Egfl7 locus in vivo
and can activate Egfl7 transcription through a regulatory element within intron 3 of the
Egfl7 locus.
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EGFL7 Functions Downstream of CASZ1 to Control Vascular Morphogenesis
To determine if CASZ1 acts through EGFL7 to regulate EC development, we depleted Egfl7
in embryos using a morpholino that left miR-126 expression intact (Figures S4A-S4E).
Strikingly, EGFL7-depletion resulted in vascular phenotypes that phenocopied CASZ1-
depletion (Figures 5A-5H, S4F-S4S). As with CASZ1-depleted embryos, we found a
reduction in density of ECs within the vitelline vein network (stage 32)(Figures 5A-5D,
S4F-S4G, S4J-S4M). Furthermore, while blood vessels did form in EGFL7-depleted
embryos, there was significantly reduced branching and intersomitic vessel sprouting at later
stages (Figures 5E-5H, S4H-S41, S4N-S4Q). Quantification of vitelline vein networks at
stage 36 revealed results similar to CASZ1-depletion whereby the total length of the
vasculature and number of branch points and intersomitic vessels of EGFL7-depleted
embryos was significantly decreased compared to controls (Figure 5I). Furthermore, like
CASZ1-depleted embryos, and in accordance with reports of EGFL7-depletion in zebrafish
(Parker et al., 2004), lumens of posterior cardinal veins of EGFL7-depleted embryos failed
to form (Figures 5J-5M). Morpholinos targeting the Dicer cleavage site of Xenopus pri-
miR-126 had no effect on Egfl7 expression (Figures S5A-S5E) and did not result in gross
defects in vessel morphology or patterning, in accordance with reports in zebrafish (Figures
S5F-S5U)(Fish et al., 2008). Consistently, lumens of posterior cardinal veins of miR-126-
depleted embryos were indistinguishable from controls (Figures S5V-S5Y). Taken together
these results imply EGFL7 functions downstream of CASZ1 to regulate angiogenesis and
vascular remodeling
Similar to our studies in Xenopus, time-lapse imaging of HUVECs revealed depletion of
EGFL7 by shRNA (shEgfl7, 11-fold decrease in mRNA; Figure 5N) phenocopied CASZ1-
depletion. Most notably, EGFL7-depleted cells demonstrated similar adhesion and
proliferation defects as those of CASZ1-depleted cells (Figure 5O, Movie S2) and also
displayed an elongated morphology similar to but not as extensive as observed in CASZ1-
depleted cells. The sprouting angiogenesis assay further demonstrated similar defects to
CASZ1-depleted cells whereby the total length of sprouts and number of branch points were
significantly decreased in EGFL7-depleted cells compared to controls (Figure 5P). Live
imaging showed failure to sprout was due to the inability of EGFL7-depleted cells to
maintain adhesion (Movie S5). Results were specific since we observed minimal effect on
expression of Casz1 or Flk1 (Figure 5N). Collectively, these studies show Egfl7 functions
downstream of CASZ1 to control vascular morphogenesis in Xenopus and humans. In
addition, miR-126 does not function downstream of CASZ1 in Xenopus vascular
development.
Egfl7 and miR-126 Function Downstream of CASZ1 to Regulate Cell Adhesion and Shape
To test if CASZ1 functions through Egfl7 or miR-126 to regulate vascular development and
morphogenesis in human ECs, we assessed if restoration of Egfl7 or miR-126 levels rescues
defects associated with CASZ1-depletion. While 29% of cells infected with shCasz1
rounded up and detached compared to 3% of control cells, infection of CASZ1-depleted
cells with adenoviral constructs expressing either human Egfl7 (Ad-Egfl7) or miR-126 (Ad-
miR-126) recovered proper adhesion as only 7.6% and 1% of cells detached, respectively
(Figures 6A, S6A-S6B, Movie S3). However, restoration of Egfl7, but not miR-126,
partially rescued EC morphology associated with CASZ1-depletion as measured by length-
to-width ratio (L:W)(Figures 6B, S6C). Restoration of either Egfl7 or miR-126 failed to
rescue proliferation defects (data not shown). Taken together, these studies demonstrate that
CASZ1 acts to control EC adhesion through direct transcriptional regulation of Egfl7 and
miR-126. These data further indicate EGFL7 and miR-126 have distinct functions in regards
to cell morphology since EGFL7 but not miR-126 can rescue cell shape changes, and further
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imply CASZ1 control of G1/S progression occurs by Egfl7- and miR-126-independent
pathways.
CASZ1 and EGFL7 Regulate RhoA
Past studies have provided evidence that two of the physiological outputs of the CASZ1/
EGFL7 pathway, cell adhesion and morphology, are directly controlled by activation of Rho
GTPases. Specifically, RhoA is required for actomyosin-dependent cell contractility and
formation of focal adhesions (FA)(Burridge and Wennerberg, 2004; Katoh et al., 2011;
Parsons et al., 2010). To identify mechanisms that mediate the physiological function of the
CASZ1/EGFL7 pathway, we aimed to determine the relationship between CASZ1/EGFL7
and RhoA. We found RhoA activity and levels were dramatically diminished in CASZ1 and
EGFL7-depleted cells, however, levels of other Rho proteins such as RhoC were unaltered
(Figure 6C, S6D-S6E). The decrease in RhoA protein occurred at the transcriptional level as
RhoA but not RhoC mRNA levels were markedly diminished in both CASZ1 and EGFL7-
depleted ECs (Figure 6D). However, RhoB levels were slightly increased possibly indicating
a compensatory mechanism for loss of RhoA (Figure 6D).
We reasoned reduction of RhoA expression in CASZ1- and EGFL7-depleted cells would
result in concomitant impaired downstream activity. Consistently, phosphorylation of
regulatory subunit of myosin light chain (p-MLC) was decreased in CASZ1-depleted cells
(Figure S6F). To further assess whether decreased RhoA activity directly plays a role in the
adhesion and cell shape defects we observe in CASZ1-depleted cells, we analyzed a panel of
cytoskeletal and FA markers. Control cells displayed discrete bundles of F-actin stress
fibers, as assayed by phalloidin staining, that contained short or punctate bands of FA
markers vinculin and phosphorylated paxillin (Figure 6E, left panels). However, CASZ1-
depletion mimicked treatment with the Rho kinase (ROCK) inhibitor Y-27632 resulting in
diffuse actin networks devoid of stress fibers and failure of vinculin and phosphorylated
paxillin to properly localize to adhesion sites on the periphery of the cell (Figure 6E, middle
panels)(Narumiya et al., 2000). This phenotype was partially rescued by restoration of Egfl7
levels in CASZ1-depleted cells (Figure 6E, right panels). Taken together these studies show
CASZ1 acts through the direct transcriptional regulation of EGFL7 to control EC adhesion
and shape via the RhoA pathway.
Discussion
In this work we demonstrate an essential and conserved role for the CASZ1/EGFL7/RhoA
pathway in vascular patterning. Collectively, these data support a mechanism whereby
CASZ1 directly binds to and maintains expression of Egfl7 in ECs. EGFL7 is then localized
extracellularly where it modulates signals between ECs and the underlying ECM. This in
turn is responsible for transcriptional upregulation and activity of the RhoA GTPase which
ultimately mediates EC contractility and adhesive properties to promote assembly, lumen
formation, and functionality of the vasculature (Figure 7).
CASZ1 Regulates EC Behavior Via EGFL7/RhoA to Promote Assembly of a Well-Branched
Vascular Network
During embryogenesis, ECs assemble into cord-like structures that undergo further
remodeling to form the primary vascular plexus. We have shown CASZ1 acts through the
direct transcriptional regulation of EGFL7 to promote two critical processes during this
period of embryogenesis: sprouting angiogenesis and lumen morphogenesis. The presence
of thickened cords lacking lumens in CASZ1-depleted embryos, together with the
observation that CASZ1-depleted ECs fail to sprout properly or adhere to extracellular
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substrates, strongly implies that CASZ1 functions through the EGFL7/RhoA pathway to
maintain proper EC adhesion during vessel assembly.
Casz1 and RhoA
RhoA has been shown to be a central component of pathways which facilitate vascular
remodeling. In this regard, RhoA has been demonstrated to be required for stress fiber
formation, acting through the actomyosin contractile machinery, and for FA formation
(Burridge and Wennerberg, 2004; Chrzanowska-Wodnicka and Burridge, 1996; Katoh et al.,
2011; Nobes and Hall, 1995). In accordance with CASZ1 acting through RhoA to promote
proper EC adhesion, we find that depleting CASZ1 phenocopies inhibition of RhoA and
leads to a lack of discrete stress fibers, decreased myosin II activity, and strikingly, the
absence of FA markers at sites of substrate contact. Moreover, these alterations in EC
adherence can all be rescued in a CASZ1-depleted background by restoration of Egfl7.
The role of RhoA in tubulogenesis has been controversial. While reports have demonstrated
RhoA activity is central for lumen formation, for example in the formation of the mouse
dorsal aorta (Strilic et al., 2009), other reports have shown that in culture RhoA is not
required for lumen formation but rather, for maintenance of patent vessels (Bayless and
Davis, 2002). However, the in vivo relevance of the latter observation is yet to be
determined since the mechanism by which lumens arise in 3D collagen culture differs
significantly from that of cord hollowing in vivo (Davis et al., 2007; Strilic et al., 2009).
Paradoxically, it has been recently demonstrated RhoA and myosin II activity must be
suppressed to promote lumen formation of mouse vessels via negative regulation by Ras
interacting protein 1 (RASIP1) (Xu et al., 2011). Collectively these studies along with our
present findings imply that a precise level of RhoA activity is required for lumen formation
with either too low or too high activity leading to failure of vascular cords to hollow and
form lumens.
The finding that RhoA protein and mRNA expression are significantly diminished in
CASZ1 and EGFL7-depleted HUVECs indicates transcriptional control of RhoA is
impaired. Very few studies to date have focused on how RhoA transcription is controlled.
While EGFL7 has been shown to interact with lysyl oxidases responsible for vascular
elastogenesis as well as some Notch receptors on both ECs and neural stem cells, it is still
unclear how these interactions may be influencing RhoA transcription or activity (Lelievre
et al., 2008; Nichol et al., 2010; Schmidt et al., 2009). However, our results would support a
mechanism by which CASZ1 modulates RhoA signaling through EGFL7 as restoration of
Egfl7 levels in CASZ1-depleted cells rescues adhesion, proper FA marker localization, and
stress fiber formation. It was recently shown that RhoA is directly activated by the Myc-
Skp2-Miz1-p300 transcriptional complex (Chan et al., 2010). Given a role for c-Myc in
embryonic vascular development and later angiogenic remodeling (Baudino et al., 2002;
Kokai et al., 2009; Rodrigues et al., 2008), it will be interesting to investigate whether
CASZ1 transcriptional regulation of Egfl7 directly plays into Myc-mediated transcriptional
control of RhoA.
Transcriptional Regulation of Egfl7 and miR-126
Studies on Egfl7 and miR-126 have identified a 5.4Kb upstream sequence that is sufficient
to drive EC-specific expression of a reporter gene in mouse, and mutation of two
evolutionarily conserved Ets binding sites within this element eliminated expression in
culture (Wang et al., 2008). We have demonstrated CASZ1 is required for expression of
Egfl7 where CASZ1 is endogenously bound to intron 3 of the Egfl7 locus in developing
embryos and depletion of EGFL7 phenocopies CASZ1-depletion in embryos and HUVEC.
Consistently, we note CASZ1 is not required for onset of Egfl7 expression in embryos but
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rather its maintenance. Based on our studies, we favor a model by which Ets factors activate
Egfl7 via an upstream element and CASZ1 binds to intron 3 and functions to maintain Egfl7
levels. This model is complementary to findings for the role of Ets factors in regulating the
spatial pattern of Egfl7 in mouse (Wang et al., 2008).
Our finding that EGFL7 and miR-126 are both regulated in a CASZ1-dependent manner in
humans is congruent with reports in mouse. However, despite complete conservation of
miR-126 across species, we also demonstrate miR-126 has undergone an evolutionarily
divergent and unique means of regulation exemplified by our findings that Xenopus
miR-126 is expressed in domains mutually exclusive to Egfl7 (i.e. somites) and expression
of Xenopus miR-126 in the vasculature is CASZ1-independent. These observations are
broadly consistent with recent reports that miR-126 transcription can occur independently of
host gene transcription through differential intronic promoters (Monteys et al., 2010).
Conclusions
The vascular system arises via concerted efforts of individual ECs to harness their unique
behaviors to assemble into tubular structures. The molecular and cellular mechanisms by
which the vasculature arises are still unclear but we have identified previously unknown
roles for CASZ1 in regulating sprouting and morphogenesis. While endothelium becomes
stabilized and quiescent after embryonic development, vessels retain sensitivity to changes
in environment due to injury, inflammation, or improper cardiac output thus making them
susceptible to vascular dysfunction. In this regard, it is interesting that human CASZ1 has
been linked to adult vascular diseases such as hypertension (Takeuchi et al., 2010). Events
resulting in vascular dysfunction during this disease are associated with aberrant ECM
remodeling, proliferation, and adhesion, all of which we have demonstrated to also be
dysregulated upon depletion of CASZ1 (Lemarie et al., 2010). Therefore it will be intriguing
to examine mechanisms by which CASZ1 itself is regulated and identify additional
transcriptional targets that could trigger development of innovative therapeutic strategies in
cardiovascular disease.
Experimental Procedures
Xenopus Embryo Collection and Morpholino Design
Preparation and collection of Xenopus embryos was performed as described (Showell et al.,
2006). Embryos were staged according to Nieuwkoop and Faber (Nieuwkoop and Faber,
1967). MOs were obtained from Gene Tools, LLC. Casz1-specific MOs used as reported
(Christine and Conlon, 2008). Egfl7-specific MO designed against acceptor region of X.
laevis exon 6 and miR-126-specific MO designed against guide dicer region of X. laevis
(Supplemental information).
In Situ Hybridization
Whole mount in situ analysis was carried out as described (Harland, 1991) using probes of
Casz1 (Christine and Conlon, 2008), Msr (Devic, 1996), Ami (Inui and Asashima, 2006),
Erg (cloned from st. 39 X. laevis cDNA), Egfl7 (cloned from st. 33-38 X. tropicalis cDNA),
and EphrinB2 (cloned from st. 39 X. laevis cDNA). miR-126 locked nucleic acid probe from
Exiqon (38523-05) and hybridization was performed according to manufacturer's
instructions at 51°C.
Chromatin Immunoprecipitation (ChIP)
Four hundred cardiovascular-enriched regions were dissected from st. 29 X. tropicalis
embryos and processed for ChIP as reported (Weinmann and Farnham, 2002) (Taranova et
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al., 2006) with following exceptions: (1)Sonication was carried out with Branson Digital
Sonifier at 20% amplitude (2.5 cycles, 30s [1s on/0.5s off]) to yield 4kb DNA fragments.
(2)Affinity-purified rabbit anti-CASZ1 polyclonal antibody was added and incubated
overnight at 4°C. (3)DNA was digested with NlaIII (NEB) and ligated into SphI-digested
(NEB) pUC19 using DNA ligation kit (Stratagene). Ligated DNA was transformed into
NEB10β electrocompetent cells. Transformants were selected by blue/white screening,
cultured, and isolated plasmids were sequenced. CASZ1 target DNA sequences were
assessed by BLAT analysis using UCSC X. tropicalis Genome Browser (http://
genome.ucsc.edu, August 2005 assembly). DNA scaffold location coordinates were
imported into the annotated Joint Genome Institute. v4.1 database (http://genome.jgi-psf.org/
Xentr4/Xentr4.home.html). Validation of targets by ChIP PCR was performed as above with
following exceptions: (1)Thirty st. 32 X. tropicalis embryos were collected and processed as
described. (2)Nuclear samples were sonicated at 20% amplitude (5 cycles, 30s [1s on/0.5s
off]) to generate ∼300bp DNA fragments.
In vivo Transcriptional Assays
Egfl7 intronic regions (introns 2,3,4,5) were subcloned into pGL3-Promoter firefly
luciferase vector (Promega). X. laevis embryos were injected at 1-cell stage with 300 pg
reporter plasmid and 10 pg Renilla reporter plasmid in presence or absence of CASZ1
mRNA. Injected embryos were cultured until st. 11.5. Ten injected embryos were lysed in
50 μl Passive Lysis Buffer (Promega) in triplicate. 20 μl of cleared lysates were assayed
using Dual-Luciferase Reporter Assay System (Promega).
Cell Culture
Pooled population of HUVEC (Lonza) were maintained in Complete EBM-2 (Lonza)
containing 10% fetal bovine serum, 100 U/mL penicillin and streptomycin and used between
passages 1-6. hCASZ1 was IP'ed from HUVECs using polyclonal rabbit anti-human CASZ1
(LifeSpan Biosciences) and probed by western blot with same antibody.
shRNA
shRNA viral constructs specific to human Casz1 and Egfl7 were obtained from Open
Biosystems TRC1 shRNA library. Casz1, Egfl7, and control scrambled sequence (Addgene)
shRNA lentiviral particles were prepared by UNC Lentiviral Core Facility. 40-50%
confluent HUVECs were infected with 1 × 106 IU lentivirus combined with 10 μg/mL
polybrene (Sigma) for 7.5 hr. Infected cells were placed under 1.5 μg/mL puromycin
selection for 3 days and processed for further analysis.
Live Time-Lapse Imaging
Cells seeded on uncoated or Fibronectin-coated (10 μg/mL) 12-well dishes, or embedded in
fibrin gel were imaged over 24 hr using Olympus IX70 inverted microscope encased in
Plexiglas housing to control internal environment (37°C, 5% CO2 and relative humidity of
60%). Images were collected by Volocity 5.4.1 software.
Immunofluorescence
Cells seeded in chamber slides (BD Falcon) were fixed with cold methanol/acetone,
blocked, and incubated with phospho-histone H3 (Millipore) or cleaved caspase-3 (Cell
Signaling) overnight. Cells were incubated with rabbit anti-Cy3 (Sigma), stained with DAPI,
and mounted (DakoCytomation). For cytoskeletal staining, cells were serum-starved
(EBM-2+0.75% FBS) overnight, half of the cells were treated with 10μM Y-27632 (Sigma).
Cells were fixed in 4% PFA, permeabilized with 0.1% Triton X-100, and incubated
overnight with anti-vinculin (Sigma), and anti-phospho-paxillin (pY118, Invitrogen). Cells
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were incubated with fluorescent secondary antibodies, stained with FITC-conjugated
phalloidin (Invitrogen) and DAPI, mounted and imaged (Zeiss 710 or 700 microscope).
Sprouting Angiogenesis Assay
Sprouting assays were performed as described (Nakatsu et al., 2003; Sweet et al., 2012).
Cells were stained with phalloidin (FITC) to visualize actin and with DRAQ5 to mark EC
nuclei, and imaged (Olympus FLV500 inverted confocal microscope, 20× objective). Assay
quantified measuring total length of protruding sprouts and number of branch points.
Western Blotting
Western blots were performed with 50 μg protein using RhoA (Santa Cruz), phosphomyosin
light chain 2 (Cell Signaling [Ser 19]), RhoC (Santa Cruz [K-12]).
Statistical Analysis
Data are expressed as means ± SEM as indicated. Statistical analysis was done by Student's
t-test and p<0.05 was considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work is supported by grants to F.L.C from NIH/NHLBI (RO1 DE018825 and RO1 HL089641). N.M.A and
K.S.C were supported by AHA awards. We are extremely grateful to faculty of Microscopy Services Lab at UNC
for microscopy help and also John Wallingford, Mark Peifer, and Keith Burridge for helpful discussions and critical
reading of manuscript.
References
Baltzinger M, Mager-Heckel AM, Remy P. Xl erg: expression pattern and overexpression during
development plead for a role in endothelial cell differentiation. Dev Dyn. 1999; 216:420–433.
[PubMed: 10633861]
Barton K, Muthusamy N, Fischer C, Ting CN, Walunas TL, Lanier LL, Leiden JM. The Ets-1
transcription factor is required for the development of natural killer cells in mice. Immunity. 1998;
9:555–563. [PubMed: 9806641]
Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, Davis AC, Ihle
JN, Cleveland JL. c-Myc is essential for vasculogenesis and angiogenesis during development and
tumor progression. Genes Dev. 2002; 16:2530–2543. [PubMed: 12368264]
Bayless KJ, Davis GE. The Cdc42 and Rac1 GTPases are required for capillary lumen formation in
three-dimensional extracellular matrices. J Cell Sci. 2002; 115:1123–1136. [PubMed: 11884513]
Burridge K, Wennerberg K. Rho and Rac take center stage. Cell. 2004; 116:167–179. [PubMed:
14744429]
Campagnolo L, Leahy A, Chitnis S, Koschnick S, Fitch MJ, Fallon JT, Loskutoff D, Taubman MB,
Stuhlmann H. EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis
and arterial injury. Am J Pathol. 2005; 167:275–284. [PubMed: 15972971]
Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9:653–660. [PubMed: 12778163]
Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;
473:298–307. [PubMed: 21593862]
Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, Wu J, Nakayama KI, Kang HY, Huang HY, et
al. Deciphering the transcriptional complex critical for RhoA gene expression and cancer
metastasis. Nat Cell Biol. 2010; 12:457–467. [PubMed: 20383141]
Charpentier et al. Page 11













Christine KS, Conlon FL. Vertebrate CASTOR is required for differentiation of cardiac precursor cells
at the ventral midline. Dev Cell. 2008; 14:616–623. [PubMed: 18410736]
Chrzanowska-Wodnicka M, Burridge K. Rho-stimulated contractility drives the formation of stress
fibers and focal adhesions. J Cell Biol. 1996; 133:1403–1415. [PubMed: 8682874]
Cleaver O, Tonissen KF, Saha MS, Krieg PA. Neovascularization of the Xenopus embryo. Dev Dyn.
1997; 210:66–77. [PubMed: 9286596]
Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA. Apelin, the ligand for the endothelial G-
protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular
development of the frog embryo. Dev Biol. 2006; 296:177–189. [PubMed: 16750822]
Davis GE, Koh W, Stratman AN. Mechanisms controlling human endothelial lumen formation and
tube assembly in three-dimensional extracellular matrices. Birth Defects Res C Embryo Today.
2007; 81:270–285. [PubMed: 18228260]
De Val S. Key transcriptional regulators of early vascular development. Arterioscler Thromb Vasc
Biol. 2011; 31:1469–1475. [PubMed: 21677289]
De Val S, Black BL. Transcriptional control of endothelial cell development. Dev Cell. 2009; 16:180–
195. [PubMed: 19217421]
Devic E, Paquereau L, Vernier P, Knibiehler B, Audigier Y. Expression of a new G protein-coupled
receptor X-msr is associated with an endothelial lineage in Xenopus laevis. Mechanisms of
Development. 1996; 59:129–140. [PubMed: 8951791]
Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY,
Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;
15:272–284. [PubMed: 18694566]
Fitch MJ, Campagnolo L, Kuhnert F, Stuhlmann H. Egfl7, a novel epidermal growth factor-domain
gene expressed in endothelial cells. Dev Dyn. 2004; 230:316–324. [PubMed: 15162510]
Harland RM. In situ hybridization: an improved whole mount method for Xenopus embryos. Meth
Cell Biol. 1991; 36:675–685.
Inui M, Asashima M. A novel gene, Ami is expressed in vascular tissue in Xenopus laevis. Gene Expr
Patterns. 2006; 6:613–619. [PubMed: 16431163]
Katoh K, Kano Y, Noda Y. Rho-associated kinase-dependent contraction of stress fibres and the
organization of focal adhesions. J R Soc Interface. 2011; 8:305–311. [PubMed: 20826475]
Kokai E, Voss F, Fleischer F, Kempe S, Marinkovic D, Wolburg H, Leithauser F, Schmidt V, Deutsch
U, Wirth T. Myc regulates embryonic vascular permeability and remodeling. Circ Res. 2009;
104:1151–1159. [PubMed: 19407242]
Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, Chen CZ, Kuo CJ. Attribution of
vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development. 2008;
135:3989–3993. [PubMed: 18987025]
Lelievre E, Hinek A, Lupu F, Buquet C, Soncin F, Mattot V. VE-statin/egfl7 regulates vascular
elastogenesis by interacting with lysyl oxidases. EMBO J. 2008; 27:1658–1670. [PubMed:
18497746]
Lelievre E, Lionneton F, Soncin F, Vandenbunder B. The Ets family contains transcriptional activators
and repressors involved in angiogenesis. Int J Biochem Cell Biol. 2001; 33:391–407. [PubMed:
11312108]
Lemarie CA, Tharaux PL, Lehoux S. Extracellular matrix alterations in hypertensive vascular
remodeling. J Mol Cell Cardiol. 2010; 48:433–439. [PubMed: 19837080]
Levine AJ, Munoz-Sanjuan I, Bell E, North AJ, Brivanlou AH. Fluorescent labeling of endothelial
cells allows in vivo, continuous characterization of the vascular development of Xenopus laevis.
Dev Biol. 2003; 254:50–67. [PubMed: 12606281]
Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson
AD, Aspelund T, et al. Genome-wide association study of blood pressure and hypertension. Nat
Genet. 2009; 41:677–687. [PubMed: 19430479]
Mandel EM, Kaltenbrun E, Callis TE, Zeng XX, Marques SR, Yelon D, Wang DZ, Conlon FL. The
BMP pathway acts to directly regulate Tbx20 in the developing heart. Development. 2010;
137:1919–1929. [PubMed: 20460370]
Charpentier et al. Page 12













Monteys AM, Spengler RM, Wan J, Tecedor L, Lennox KA, Xing Y, Davidson BL. Structure and
activity of putative intronic miRNA promoters. RNA. 2010; 16:495–505. [PubMed: 20075166]
Nakatsu MN, Sainson RC, Aoto JN, Taylor KL, Aitkenhead M, Perez-del-Pulgar S, Carpenter PM,
Hughes CC. Angiogenic sprouting and capillary lumen formation modeled by human umbilical
vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1.
Microvasc Res. 2003; 66:102–112. [PubMed: 12935768]
Narumiya S, Ishizaki T, Ufhata M. Use and properties of ROCK-specific inhibitor Y-27632. Methods
in Enzymology. 2000; 325:273–284. [PubMed: 11036610]
Nichol D, Shawber C, Fitch MJ, Bambino K, Sharma A, Kitajewski J, Stuhlmann H. Impaired
angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. Blood. 2010;
116:6133–6143. [PubMed: 20947685]
Nieuwkoop, PD.; Faber, J. Normal Table of Xenopus laevis (Daudin). Amsterdam, North Holland:
1967.
Nikolic I, Plate KH, Schmidt MH. EGFL7 meets miRNA-126: an angiogenesis alliance. J Angiogenes
Res. 2010; 2:9. [PubMed: 20529320]
Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal
complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell. 1995; 81:53–62.
[PubMed: 7536630]
Parker LH, Schmidt M, Jin SW, Gray AM, Beis D, Pham T, Frantz G, Palmieri S, Hillan K, Stainier
DY, et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation.
Nature. 2004; 428:754–758. [PubMed: 15085134]
Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular
tension. Nat Rev Mol Cell Biol. 2010; 11:633–643. [PubMed: 20729930]
Patan S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and
remodeling. J Neurooncol. 2000; 50:1–15. [PubMed: 11245270]
Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;
146:873–887. [PubMed: 21925313]
Rodrigues CO, Nerlick ST, White EL, Cleveland JL, King ML. A Myc-Slug (Snail2)/Twist regulatory
circuit directs vascular development. Development. 2008; 135:1903–1911. [PubMed: 18469221]
Schmidt MH, Bicker F, Nikolic I, Meister J, Babuke T, Picuric S, Muller-Esterl W, Plate KH, Dikic I.
Epidermal growth factor-like domain 7 (EGFL7) modulates Notch signalling and affects neural
stem cell renewal. Nat Cell Biol. 2009; 11:873–880. [PubMed: 19503073]
Showell C, Christine KS, Mandel EM, Conlon FL. Developmental expression patterns of Tbx1, Tbx2,
Tbx5, and Tbx20 in Xenopus tropicalis. Dev Dyn. 2006; 235:1623–1630. [PubMed: 16477648]
Strilic B, Kucera T, Eglinger J, Hughes MR, McNagny KM, Tsukita S, Dejana E, Ferrara N, Lammert
E. The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell.
2009; 17:505–515. [PubMed: 19853564]
Sweet DT, Chen Z, Wiley DM, Bautch VL, Tzima E. The adaptor protein Shc integrates growth factor
and ECM signaling during postnatal angiogenesis. Blood. 2012; 119:1946–1955. [PubMed:
22096252]
Takeuchi F, Isono M, Katsuya T, Yamamoto K, Yokota M, Sugiyama T, Nabika T, Fujioka A, Ohnaka
K, Asano H, et al. Blood pressure and hypertension are associated with 7 loci in the Japanese
population. Circulation. 2010; 121:2302–2309. [PubMed: 20479155]
Taranova OV, Magness ST, Fagan BM, Wu Y, Surzenko N, Hutton SR, Pevny LH. SOX2 is a dose-
dependent regulator of retinal neural progenitor competence. Genes Dev. 2006; 20:1187–1202.
[PubMed: 16651659]
Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson
EN. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis.
Dev Cell. 2008; 15:261–271. [PubMed: 18694565]
Warkman AS, Zheng L, Qadir MA, Atkinson BG. Organization and developmental expression of an
amphibian vascular smooth muscle alpha-actin gene. Dev Dyn. 2005; 233:1546–1553. [PubMed:
15965984]
Weinmann AS, Farnham PJ. Identification of unknown target genes of human transcription factors
using chromatin immunoprecipitation. Methods. 2002; 26:37–47. [PubMed: 12054903]
Charpentier et al. Page 13













Xu K, Sacharidou A, Fu S, Chong DC, Skaug B, Chen ZJ, Davis GE, Cleaver O. Blood Vessel
Tubulogenesis Requires Rasip1 Regulation of GTPase Signaling. Dev Cell. 2011; 20:526–539.
[PubMed: 21396893]
Charpentier et al. Page 14














• CASZ1 is a conserved transcription factor required for vascular patterning
• CASZ1 controls endothelial cell adhesion, contractility, and proliferation.
• This control is exerted through the regulation of target genes Egfl7 and
miR-126.
• RhoA functions downstream of CASZ1/EGFL7 to mediate endothelial cell
behavior.
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Figure 1. CASZ1 Expression in Vascular ECs is Evolutionarily Conserved
(A) In situ analysis of Casz1 Xenopus embryos (stage 41). Lateral view with anterior to left.
Casz1 is expressed in vascular structures including vitelline vein network (vvn, enlarged
panel on right).
(B) CASZ1 (green) co-localizes with PECAM (red) in neural blood vessels of E14.5 mouse
embryos.
(C) RT-PCR analysis of human Casz1 in HUVEC cDNA. Gapdh was used as loading
control.
(D) Immunoprecipitation (IP) of CASZ1 from HUVECs. Control lane (left) represents IP
with no antibody (Ab). Arrowhead represents 125kD human CASZ1.
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Figure 2. CASZ1 is Required for Vascular Development and Lumen Formation
(A-H) In situ analysis with EC marker Msr control and CASZ1-depleted embryos (stages
32-36; lateral view with anterior to left). Vessel patterning and branching within vitelline
vein network (vvn) are severely compromised at stage 32 in CASZ1-depleted embryos (A,C
high magnification of vvn in B,D) and stage 36 (E,G high magnification of vvn in F,H).
Note poor sprouting of intersomitic vessels (isv) in CASZ1-depleted embryos at both stages
(enlarged box in A,C,E,G). (n=10 embryos/condition/stage, 3 independent experiments).
(I) Quantification of vascular defects in control and CASZ1-depleted embryos (stage 36)
representing combined total length of vessels, number of branch points within vvn, and
number of isvs/embryo, respectively. Data represent mean ± SEM. (n=7 control and 10
Casz1 MO embryos). *: p<0.05; **:p<0.01; ***:p<0.001.
(J-Q) Histological analysis illustrates time course of lumen formation in Xenopus from
stages 29-39 (J-M). Note posterior cardinal vein (pcv) lumens begin to open between stages
32 and 36 in control embryos (K,L) but fail to form in CASZ1-depleted embryos (N-Q).
Dorsal is top, ventral is bottom. Arrowheads correspond to positions of pcv which are
enlarged in lower panels (n=2-5 embryos/condition/stage). See also Figure S1.
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Figure 3. CASZ1 Regulates EC Behavior
(A) mRNA levels of Casz1 after infection of HUVECs with shCasz1. Casz1 is decreased by
16-fold. mRNA levels relative to Rps29 ± SEM. ***: p<0.001.
(B) Phase contrast images of control and shCasz1 HUVECs. Controls display cobblestone-
like morphology while CASZ1-depleted cells are thin and elongated (red arrowheads for
examples of each).
(C) Time-lapse images of control and shCasz1 cells. Red arrowheads represent dividing
control cell and rounded up CASZ1-depleted cell. Minutes elapsed presented at bottom
right, taken every 5 min for 24 hr. Red arrow refers to elongated shCasz1 cell with trailing
edge defects. Graph represents quantification of cells that round up and detach during
imaging. Data represent mean ± SEM of 3 experiments conducted on independent batches of
shRNA-infected cells (n=200 cells). **:p<0.01.
(D) Sprouting angiogenesis assay was performed with control and CASZ1-depleted
HUVEC. On day 6, cultures were fixed and stained for phalloidin (green) and DRAQ5
(blue). Graphs represent mean ± SEM of total sprout length and number of branch points/
bead (n=11 beads/condition). Experiments were repeated twice on independent batches of
shRNA-infected cells. **:p<0.01; ***p<0.001. See also Figure S2, Movies S1 and S4.
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Figure 4. CASZ1 Directly Activates Egfl7 Transcription
(A) Illustration of cardiovascular-enriched region dissected from X. tropicalis for chromatin
immunoprecipitation (ChIP).
(B) Genomic structure of Xenopus Egfl7 locus denoting CASZ1 ChIP fragment. White
boxes: exons; shaded boxes, miR-126 in intron 7 and intronic region potentially containing
CASZ1 element (+/- 4kb).
(C-J) In situ analysis of Egfl7 of stages 29-39 control and CASZ1-depleted embryos (lateral
view with anterior to left). Note downregulation of Egfl7 in vitelline vein network (vvn) and
intersomitic vessels (isv) in CASZ1-depleted embryos. Pcv-posterior cardinal vein.
(K) Relative mRNA expression of Egfl7, miR-126, and Flk1 after infection of HUVECs
with shCasz1. mRNA levels relative to Rps29 ± SEM. ***:p<0.001; NS: not significant.
(L) Schematic demarcating Egfl7 genomic DNA regions (in bp) tested for transcriptional
activation. E1 (-55–1614) within intron 3 but not E2 (1773–3840) resulted in increased
luciferase (luc) activity.
(M) Egfl7 genomic region E1 in presence or absence of Casz1. Bars represent fold increase
in activity relative to control ± SEM. Experiments were repeated twice on independent
batches of embryos, **:p<0.01.
(N) Identification of 90bp region endogenously bound by CASZ1located within non-
overlapping region of E1.2 (113-227) PCR amplicon. See also Figure S3.
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Figure 5. EGFL7-Depletion in Embryos and HUVECs Phenocopies CASZ1-Depletion
(A-H) In situ analysis with EC marker Msr control and EGFL7-depleted embryos (stages
32-36, lateral view with anterior to left). Note lack of branching in vitelline vein network
(vvn) at stage 32 (A,C high magnification of vvn in B,D) and stage 36 (E,G high
magnification of vvn in F,H). Intersomitic vessel (isv) sprouting is also impaired (A,C,E,G).
(n=10 embryos/condition/stage, 3 independent experiments).
(I) Quantification of vascular defects control and EGFL7-depleted embryos (stage 36)
representing total vessel length, number of branch points within vvn, and number of isvs/
embryo. Data represent mean ± SEM. (n=7 control and 10 Egfl7 MO embryos). *:p<0.05;
**:p<0.01; ****:p<0.0005.
(J-M) Histological analysis reveals lumenless posterior cardinal veins (pcv) in stage 36 (K)
and stage 39 (M) Control and EGFL7-depleted embryos (J,L), dorsal top, ventral bottom,
arrowheads correspond to pcv positions enlarged in lower panels (n=3 embryos/condition/
stage).
(N) mRNA expression of Egfl7, miR-126, Casz1, and Flk1 after infection of HUVECs with
shEgfl7. Egfl7 is decreased 11-fold. mRNA levels relative to Rps29 ± SEM. ***:p<0.001;
NS: not significant.
(O) Quantification of cells that round up and detach during imaging. Data represent mean ±
SEM of 2 experiments conducted on independent batches of shRNA-infected cells. (n=100
cells). **:p<0.01.
(P) Sprouting angiogenesis assay was performed with control and EGFL7-depleted HUVEC.
On day 6, cultures were fixed and stained for phalloidin (green) and DRAQ5 (blue). Graphs
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represent mean ± SEM of total sprout length and number of branch points/bead (n=11 beads/
condition). Experiments were repeated twice on independent batches of shRNA-infected
cells. **:p<0.01; ***p<0.001. See also Figures S4-S5 and Movies S2 and S5.
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Figure 6. EGFL7 and miR-126 Play Distinct Roles Downstream of CASZ1
(A) Quantification of cells co-infected with shCasz1 and Ad-Egfl7 or Ad-miR-126 that
round up and detach versus shCasz1 or control shRNA alone. Data represent mean ± SEM
of 2 average experiments conducted on independent batches of shRNA-infected cells.
(n=100 cells). **:p<0.01; ****:p<0.0005.
(B) Quantification of cell morphology determined by measuring length-to-width (L:W)
ratio. Morphology was improved in cells co-infected with shCasz1 and Ad-Egfl7 but not in
cells co-infected with Ad-miR-126. Data represent mean ± SEM of 3 experiments conducted
on independent batches of shRNA-infected cells. (n=300-600 cells). **:p<0.01;
****:p<0.0005.
(C) RhoA protein expression in shRNA-infected HUVECs. RhoA levels were markedly
decreased by depletion of CASZ1 and EGFL7. Graph of densitometry of RhoA levels
relative to GAPDH.
(D) Relative RhoA, RhoB, and RhoC mRNA expression after shRNA infection. mRNA
levels relative to Rps29 ± SEM. *:p<0.05; ***:p<0.001; NS: not significant.
(E) Stress fibers and FAs disrupted in CASZ1-depleted HUVECs resemble cells treated with
ROCK inhibitor Y-27632 (10μM). Restoration of Egfl7 in CASZ1-depleted cells rescues
proper FA localization. Phalloidin marks F-actin filaments (green), vinculin (red) and
phosphorylated paxillin (yellow) mark FAs. See also Figure S6 and Movie S3.
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Figure 7. A model describing CASZ1 function in endothelial cells
CASZ1 functions by binding to an intronic element within the Egfl7 locus to activate proper
levels of Egfl7 in endothelial cells. EGFL7 is then secreted to the extracellular matrix
(ECM) where it likely binds cell-surface receptors which signal downstream to activate
RhoA expression. Consequently, RhoA signaling modulates endothelial cell behaviors such
as adhesion and contractility to promote vessel assembly and morphogenesis.
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